deltatrials
Completed PHASE2 NCT00006359

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer

Sponsor: Alliance for Clinical Trials in Oncology

Updated 7 times since 2017 Last updated: Jul 15, 2016 Started: Sep 30, 2000 Primary completion: Oct 31, 2007 Completion: Mar 31, 2012

Listed as NCT00006359, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

Show 2 earlier versions
  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States, Buffalo, United States, Camden, United States, Charlotte, United States, Columbia, United States, Columbus, United States, Danville, United States, Elkton MD, United States, Fall River, United States, Goldsboro, United States and 10 more location s